Growth hormone has not been shown to increase the incidence of scoliosis. In all reported cases, IH-associated signs and symptoms resolved after termination of therapy or a reduction of the growth hormone dose. Funduscopic examination of patients is recommended at the initiation and periodically during the course of growth hormone therapy. As with any protein, local or systemic allergic reactions may occur. Changes in thyroid hormone laboratory measurements may develop during Protropin treatment of children who lack adequate endogenous growth hormone secretion.
Untreated hypothyroidism prevents optimal response to Protropin.
Therefore, patients should have periodic thyroid function tests and should be treated with thyroid hormone when indicated. If glucocorticoid replacement is required, the dose should be carefully adjusted. Animal reproduction studies have not been conducted with Protropin. It is also not known whether Protropin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Protropin should be given to a pregnant woman only if clearly needed.